These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 19369458

  • 1. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 2. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 3. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [Abstract] [Full Text] [Related]

  • 4. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 5. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 6. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
    Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O.
    Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
    [Abstract] [Full Text] [Related]

  • 7. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 8. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P.
    Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231
    [Abstract] [Full Text] [Related]

  • 9. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 15; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 10. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 11. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb 15; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 12. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar 15; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.
    Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K, Mizuno K.
    Ther Apher Dial; 2009 Jun 15; 13(3):179-85. PubMed ID: 19527463
    [Abstract] [Full Text] [Related]

  • 14. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 Jun 15; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

  • 15. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
    Arthritis Rheum; 2008 Aug 15; 58(8):2257-67. PubMed ID: 18668547
    [Abstract] [Full Text] [Related]

  • 16. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A, Inaba M, Furumitsu Y, Okamoto K, Yukioka K, Goto H, Nishizawa Y.
    Biomed Pharmacother; 2010 Feb 15; 64(2):107-12. PubMed ID: 19944558
    [Abstract] [Full Text] [Related]

  • 17. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan 15; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 18. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr 15; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 19. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 15; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 20. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 15; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.